Network Meta-Analysis: Which Type of Olive Oil Best for CV Risk?

This 2019 systematic review and network meta-analysis, published in Nutrition, Metabolism & Cardiovascular Diseases, pooled 13 randomized controlled trials to compare the effects of four different types of olive oil -- refined, mixed, low-phenolic extra virgin, and high-phenolic extra virgin -- on cardiovascular risk factors. According to PubMed (DOI), high-phenolic extra virgin olive oil ranked first across LDL cholesterol, oxidized LDL, and systolic blood pressure -- the three outcomes where olive oil type made a measurable difference.

Why This Study Matters

Most olive oil RCTs compare olive oil to some other fat -- butter, sunflower oil, the typical Western diet. Far fewer trials compare different kinds of olive oil to each other. That gap matters because the consumer market includes a wide range of products at very different prices, from generic refined olive oil to first-cold-pressed extra virgin oils from single estates. Whether the price difference corresponds to a measurable health difference has been an open question.

A pairwise meta-analysis can only compare two interventions at a time. A network meta-analysis -- the design used here -- pools indirect and direct comparisons across multiple interventions simultaneously, producing a ranked ordering of treatments for each outcome. It is the appropriate statistical tool for the question "which type works best," provided enough trials exist with overlapping comparators to form a connected network.

This 2019 analysis assembled 13 RCTs (16 reports) with 611 participants in total, sufficient to construct that network for seven cardiovascular outcomes including LDL cholesterol, HDL cholesterol, total cholesterol, triglycerides, systolic and diastolic blood pressure, and oxidized LDL.

How It Was Designed

The investigators searched MEDLINE, Web of Science, and the Cochrane Central Register through 2019, including RCTs with at least three weeks of intervention that compared at least two of the following olive oil categories head-to-head: refined olive oil (ROO), mixed olive oil (MOO), low-phenolic extra virgin or virgin olive oil (LP-VOO/EVOO), and high-phenolic extra virgin or virgin olive oil (HP-VOO/EVOO).

The phenolic classification is worth understanding. The threshold for high-phenolic in this analysis broadly aligned with the EFSA framework that authorized a health claim for olive oil polyphenols at 5 mg of hydroxytyrosol and derivatives per day. High-phenolic oils in the included trials typically supplied 200 to 500 mg of polyphenols per kilogram of oil; low-phenolic oils typically supplied less than 100 mg/kg; refined oils typically supplied near-zero polyphenols.

The 13 included RCTs covered 611 mainly healthy participants aged 26 to 70. Random-effects network meta-analysis estimated mean differences for each outcome, and the surface under the cumulative ranking curve (SUCRA) approach -- with corresponding P-scores -- produced a quantitative ranking of which olive oil type was best for each outcome.

What They Found

High-phenolic extra virgin olive oil ranked first across three of the seven outcomes; for the other four (HDL, total cholesterol, triglycerides, diastolic blood pressure), no significant differences emerged between types:

Outcome	Best-Ranked Type	SUCRA / P-score	What It Measures
LDL cholesterol	HP-EVOO (best)	0.83	Atherogenic cholesterol
Oxidized LDL	HP-EVOO (best)	0.88	Plaque-driving form of LDL
Systolic blood pressure	HP-EVOO (best)	0.75	Hypertension risk marker
HDL cholesterol	No significant difference	--	Protective cholesterol
Total cholesterol	No significant difference	--	Total blood cholesterol
Triglycerides	No significant difference	--	Blood lipid fraction
Diastolic blood pressure	No significant difference	--	Resting heart-relaxation pressure

Green indicates outcomes where high-phenolic EVOO ranked first. SUCRA / P-score ranges from 0 to 1; 1 represents the best-ranked treatment for that outcome.

A direct head-to-head comparison showed high-phenolic EVOO reduced LDL cholesterol by 0.14 mmol/L (95% CI: -0.28 to -0.01) compared to low-phenolic varieties. Both high- and low-phenolic EVOO reduced systolic blood pressure by approximately 3 mmHg compared to refined olive oil. The secondary analyses also detected a clear dose-response relationship: higher phenolic intake from olive oil correlated with lower systolic blood pressure and lower oxidized LDL values.

Reading the Results

The findings group into two interpretive observations worth understanding together.

Phenolic content drives the difference. The three outcomes where olive oil type mattered -- LDL, oxidized LDL, and systolic blood pressure -- are all mechanistically linked to oxidative stress and endothelial function. These are precisely the pathways through which olive oil polyphenols are known to act in mechanistic studies. The secondary dose-response analyses formalized this: higher phenolic intake corresponded to lower oxidized LDL and lower systolic blood pressure in a continuous gradient. The variety distinction is not arbitrary -- it tracks the underlying chemistry.

The non-phenolic outcomes were similar across types. HDL cholesterol, total cholesterol, triglycerides, and diastolic blood pressure did not differ between the four olive oil categories. This is consistent with what mechanism would predict: the monounsaturated fat content (which drives general lipid effects) is similar across all olive oil types, while the polyphenol content (which drives oxidative and inflammatory effects) is what varies. The outcomes that respond to monounsaturated fat alone do not discriminate between varieties; the outcomes that respond to polyphenols do.

The certainty of evidence is rated as low to moderate. The 13 included RCTs were mostly small and short-duration (3 weeks to several months), with mainly healthy participants -- conditions under which biomarker shifts are detectable but population-level cardiovascular event reductions cannot be established. The network meta-analysis is hypothesis-generating for the variety distinction, not definitive proof.

What Didn't Change

For HDL cholesterol, total cholesterol, triglycerides, and diastolic blood pressure, no significant differences were observed between any of the four olive oil types. The variety distinction matters specifically for outcomes linked to oxidative stress and endothelial function, not for the broader lipid panel.

The analysis also does not directly compare olive oil to other fats. Its scope is within-olive-oil comparisons, not olive oil vs. butter or canola. The cardiovascular benefit of olive oil broadly is established by other meta-analyses and the PREDIMED trial; this analysis answers the narrower question of which type within olive oil performs best.

Broader Context

This 2019 network meta-analysis provides the strongest direct biomarker evidence to date that phenolic content -- not olive oil broadly -- carries the cardiovascular signal. It aligns with the 2022 Donat-Vargas Spanish cohort finding that virgin olive oil (high-phenolic) reduced mortality while common olive oil (low-phenolic) did not. It aligns with the PREDIMED trial (2013, republished 2018 in NEJM), which used a defined EVOO intervention and showed 30% lower cardiovascular events. It aligns with the 2025 hydroxytyrosol RCT, which isolated the dominant olive polyphenol and demonstrated significant improvements across seven oxidative stress and inflammation biomarkers.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg of hydroxytyrosol and derivatives per day. The Schwingshackl meta-analysis effectively validates that EFSA threshold from the opposite direction: above the threshold, olive oil polyphenols measurably improve LDL, oxidized LDL, and systolic blood pressure; below it (refined olive oil), they do not.

Related Research

Continue exploring olive oil and polyphenol science:

• High-Phenolic vs Low-Phenolic Olive Oil: Meta-Analysis of 26 RCTs
• Olive Oil and Stroke Risk: A 101,460-Person Meta-Analysis
• Reviewing the Evidence: Olive Oil's Cardiovascular Effects (Tarabanis 2023)

Source: View the original study on PubMed

Olivea's Dosage

The included trials used olive oil intakes typically ranging from 25 to 50 grams per day. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams; two tablespoons (28 grams) is within the trial range. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving, well above the 5 mg/day EFSA threshold associated with the high-phenolic category; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.